scispace - formally typeset
Open AccessJournal ArticleDOI

The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro

TLDR
Results suggest that coselection of rtL80V/I and rtM204I/V occurs because the former compensates for the loss of replication efficiency associated with the acquisition of LMV resistance, particularly in the case of rm204I.
Abstract
Long-term lamivudine (LMV) treatment of chronic hepatitis B almost inevitably engenders viral resistance. Mutations that result in the replacement of the methionine at position 204 of the deoxynucleoside triphosphate-binding site of the hepatitis B virus (HBV) reverse transcriptase (rt) by isoleucine, valine, or (rarely) serine (rtM204I/V/S) confer high-level resistance to LMV but reduce replication efficiency. The subsequent selection or coselection of secondary mutations that partially restore replication efficiency is common and may influence drug resistance. Genotyping has shown that LMV treatment can select for HBV rtL80V/I mutants, but their prevalence and phenotype have not been documented. Analysis of a large sequence database revealed that rtL80V/I occurred almost exclusively in association with LMV resistance, and 85% of these isolates encoded rtL80I. Coselection of rtL80V/I occurred in 46% of isolates in which LMV resistance was attributable to rtM204I but only 9% of those in which resistance was attributable to rtM204V. Moreover, rtL80V/I did not occur in HBV genotype A isolates but occurred at similar frequencies in genotype B, C, and D isolates. In vitro phenotyping showed that although the rtL80I mutant by itself replicated less efficiently and was hypersensitive to LMV compared to the replication efficiency and sensitivity of its wild-type parent, the presence of rtL80I enhanced the replication efficiency of rt204I/V mutants without significantly affecting LMV resistance. Molecular modeling revealed that rt80 does not interact directly with the enzyme's substrates. Collectively, these results suggest that coselection of rtL80V/I and rtM204I/V occurs because the former compensates for the loss of replication efficiency associated with the acquisition of LMV resistance, particularly in the case of rtM204I.

read more

Citations
More filters
Journal ArticleDOI

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.

Nadia Warner, +1 more
- 01 Jul 2008 - 
TL;DR: The selection of rtA181T/sW172* reduced the typical extent of virological breakthrough, resulting in a missed diagnosis of drug resistance if viral load was used as the only criterion for drug failure, necessitating HBV polymerase chain reaction sequencing or other genotypic methods to diagnose antiviral drug resistance in these cases.
Journal ArticleDOI

Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.

TL;DR: Novel nucleoside/nucleotide analogs in advanced clinical trials include phosphonates similar to adefovir or ten ofovir, and new tenofovir derivatives with improved pharmacological properties.
Journal ArticleDOI

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

TL;DR: The high number of tolerated and resistant ETVr substitutions is consistent with models predicting that the mechanism for ETVR is through enhancement of LVDr changes in the RT deoxyribonucleotide triphosphate (dNTP)‐binding pocket.
Journal ArticleDOI

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.

TL;DR: Full-length hepatitis B virus (HBV) reverse transcriptase (RT) sequences were amplified and sequenced among Chinese patients with chronic hepatitis B, and Genotypes B and C each showed several preferred positions to mutate.
Book ChapterDOI

Antiviral Resistance and Impact on Viral Replication Capacity: Evolution of Viruses Under Antiviral Pressure Occurs in Three Phases

TL;DR: This chapter provides an overview regarding the evolution of different viruses (HIV, HBV, HCV, and Influenza) under pressure of antiviral therapy.
References
More filters
Journal ArticleDOI

SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.

Nicolas Guex, +1 more
- 01 Jan 1997 - 
TL;DR: An environment for comparative protein modeling is developed that consists of SWISS‐MODEL, a server for automated comparativeprotein modeling and of the SWiss‐PdbViewer, a sequence to structure workbench that provides a large selection of structure analysis and display tools.
Journal ArticleDOI

Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA

TL;DR: The structure of the HIV-1 RT/DNA/Fab complex should aid the understanding of general mechanisms of nucleic acid polymerization and AIDS therapies may be enhanced by a fuller understanding of drug inhibition and resistance emerging from these studies.
Journal ArticleDOI

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

TL;DR: A DNA sequence database that includes a 500–base pair region of the HBV polymerase gene from 20 patients with clinical manifestations of lamivudine resistance is reported, revealing two patterns of amino acid substitutions in the tyrosine, methionine, as partate, aspartate (YMDD) nucleotide‐binding locus of theHBV polymerases.
Journal ArticleDOI

Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region

TL;DR: The new consensus rt domain numbering system is genotype independent and allows investigators to number any previously and newly discovered antiviral‐related amino acid change in a standardized manner.
Related Papers (5)